HuniLife
- Biotech or pharma, therapeutic R&D
Hunilife is a clinical stage biotech company, pioneering in TGF-b inhibitor with unique MOA. HuniLife enables the first proteinase-targeting antibody to regulate TGF-b for improving PD1/PD-L1 antibody, radiation therapy, and chemotherapy for cancer treatment. This unique MOA emphasizes on TGF-B inhibition mainly in the tumor microenvironment. This antibody is now in phase 1/2 trial for MM and PDAC.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}